Cannabigerol
1Provenance card
the boundary, as counts
Sources
3633 with DOI
4 strong · 30 moderate · 2 weak
Compilations
12026-05-12T21:58:18.962Z
pipeline-v5 · prompt hash not recorded — run predates 2026-09
Decisions
21last ruled 2026-06-04
0 awaiting a ruling
Issued documents
52026-10-19T20:31:05.115Z
notice · info card · emergency
Searches
280 with no results
queries and counts on the build
Claims checked
8141 supported
41 supported · 40 not
Correspondence
0received
consent field ships in Phase 4
Edges
262
derivations recorded for this entity
Complete over 36 sources, 1 compilation, and 21 decisions.Not here: the private journal (never).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/cbg/archive
Timeline
what happened, newest first — claims, searches and artifacts stay inside Build
- 2026-10-19issueIssued emergency
- 2026-10-19issueIssued info_card
- 2026-09-24srcEfficacy of combined therapy with fish oil and phytocannabinoids in murine intestinal inflammation
- 2026-09-24srcCannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated rats
- 2026-09-24srcNeuroprotective properties of cannabigerol in Huntington's disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice
- 2026-09-24srcChemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms.
- 2026-09-24srcBeneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease
- 2026-09-24srcNeuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1G93A transgenic mice, an experimental model of amyotrophic lateral sclerosis
- 2026-09-24srcIn silico insights on the binding site and function of cannabinoids and cannabinoid acids on human 5-HT1A receptor
- 2026-09-24srcDifferences in receptor binding affinity of several phytocannabinoids do not explain their effects on neural cell cultures.
- 2026-09-24srcAntidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L.
- 2026-09-24srcPharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB1, CB2 and CB1/CB2 heteromer receptors
- 2026-09-24srcSafety assessment and redox status in rats after chronic exposure to cannabidiol and cannabigerol
- 2026-09-24srcComparison on the mechanism and potency of hepatotoxicity among hemp extract and its four major constituent cannabinoids
- 2026-09-24srcCould cannabigerol protect against neuroinflammation? Insights from an in vitro microglial study
- 2026-09-24srcUncovering the Hidden Antibiotic Potential of Cannabis
- 2026-09-24srcAntibacterial cannabinoids from Cannabis sativa: a structure-activity study.
- 2026-09-24srcIn vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa
- 2026-09-24srcAcute effects of cannabigerol on anxiety, stress, and mood: a double-blind, placebo-controlled, crossover, field trial
- 2026-09-24srcPhytocannabinoids: a unified critical inventory
- 2026-09-24srcEffects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes
- 2026-09-24srcHigh Cannabigerol Hemp Extract Moderates Colitis and Modulates the Microbiome in an Inflammatory Bowel Disease Model
- 2026-09-24srcBenefits of VCE-003.2 against inflammation-driven neuronal deterioration in experimental Parkinson's disease: involvement of different binding sites at PPAR-gamma
- 2026-09-24srcOral administration of the cannabigerol derivative VCE-003.2 promotes subventricular zone neurogenesis and protects against mutant huntingtin-induced neurodegeneration
- 2026-09-24srcCannabigerol and Cannabinoid Receptors in Major Depressive Disorder: Network Pharmacology, Molecular Docking, and In-vivo Analysis
- 2026-09-24srcCannabigerol and cannabichromene in Cannabis sativa L.
- 2026-09-24srcCannabis sativa: The Plant of the Thousand and One Molecules
- 2026-09-24srcMetabolism, pharmacokinetics, and bioavailability of cannabigerol in horses following intravenous and oral administration
- 2026-09-24srcTherapeutic Potential of Phytocannabinoid Cannabigerol for Multiple Sclerosis: Modulation of Microglial Activation In Vitro and In Vivo
- 2026-09-24srcShort-Term Incubation of H9c2 Cardiomyocytes with Cannabigerol Attenuates Diacylglycerol Accumulation in Lipid Overload Conditions
- 2026-09-24srcEffects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes
- 2026-09-24srcAnti-Inflammatory Effects of Cannabigerol in Rheumatoid Arthritis Synovial Fibroblasts and Peripheral Blood Mononuclear Cell Cultures Are Partly Mediated by TRPA1
- 2026-09-24srcCannabigerol Attenuates Memory Impairments, Neurodegeneration, and Neuroinflammation Caused by Transient Global Cerebral Ischemia in Mice
- 2026-09-24srcIn Vitro and Clinical Evaluation of Cannabigerol (CBG) Produced via Yeast Biosynthesis
- 2026-09-24srcSynthetic Pathways to Non-Psychotropic Phytocannabinoids as Promising Molecules to Develop Novel Antibiotics: A Review.
- 2026-09-24srcA comparison of the ocular and central effects of delta 9-tetrahydrocannabinol and cannabigerol
- 2026-09-24srcHistory of Cannabigerol Discovery
- 2026-09-24srcCBG Legal Status 2025 - Multiple Jurisdictions
- 2026-09-04issueIssued emergency
- 2026-09-04issueIssued info_card
- 2026-09-04issueIssued notice
- 2026-06-04proposal19 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
- 2026-06-04publicationPublication — backfill
- 2026-05-12revisionRevision 1
- 2026-05-12genGeneration — pipeline-v5 · with 5 morepipeline-v5
- 2026-05-12rungeneration run
The same entries, as forms: six forms.